Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has earned an average rating of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $8.00.

A number of analysts recently commented on the company. B. Riley Financial began coverage on Whitehawk Therapeutics in a research report on Thursday, June 25th. They set a “buy” rating and a $10.00 price target for the company. Citizens Jmp began coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 target price for the company. Weiss Ratings downgraded Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, June 5th. Oppenheimer reissued an “outperform” rating and issued a $7.00 target price on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Finally, Wall Street Zen downgraded Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th.

Insiders Place Their Bets

In other Whitehawk Therapeutics news, CEO David James Lennon sold 14,500 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $3.38, for a total value of $49,010.00. Following the completion of the sale, the chief executive officer directly owned 518,622 shares of the company’s stock, valued at $1,752,942.36. This trade represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Bryan Ball sold 92,460 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total value of $336,554.40. Following the completion of the sale, the insider directly owned 397,106 shares of the company’s stock, valued at $1,445,465.84. This represents a 18.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 695,830 shares of company stock valued at $2,553,026 over the last ninety days. 49.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Whitehawk Therapeutics

A number of large investors have recently made changes to their positions in WHWK. Quadrature Capital Ltd bought a new position in shares of Whitehawk Therapeutics in the fourth quarter worth $28,000. OMERS ADMINISTRATION Corp bought a new position in shares of Whitehawk Therapeutics in the first quarter worth $40,000. ABG Innovation Capital Partners III GP Ltd bought a new position in shares of Whitehawk Therapeutics in the third quarter worth $51,000. Dimensional Fund Advisors LP bought a new position in shares of Whitehawk Therapeutics in the third quarter worth $84,000. Finally, Squarepoint Ops LLC bought a new position in shares of Whitehawk Therapeutics in the third quarter worth $159,000. 52.08% of the stock is owned by institutional investors.

Whitehawk Therapeutics Trading Up 6.0%

Shares of WHWK opened at $4.41 on Tuesday. The company has a market capitalization of $218.07 million, a price-to-earnings ratio of -2.63 and a beta of 0.77. The stock has a 50 day moving average of $4.28 and a 200 day moving average of $3.50. Whitehawk Therapeutics has a 12 month low of $1.57 and a 12 month high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. As a group, equities research analysts predict that Whitehawk Therapeutics will post -1.37 earnings per share for the current year.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.